Everest Medicines Limited recently announced positive results from an ongoing Phase 1b/2a clinical trial of their next-generation covalent reversible Bruton's tyrosine kinase $(BTK.AU)$ inhibitor, EVER001 (previously known as XNW1011), for the treatment of primary membranous nephropathy (pMN). These results were presented at the 62nd Congress of the European Renal Association (ERA 2025) during a focused oral session. The company continues to advance its innovative mRNA cancer vaccine and in-vivo CAR-T programs, while also focusing on increasing sales and expanding the reach of its other products such as NEFECON® and XERAVA®.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。